GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (OTCPK:HGENQ) » Definitions » Earnings per Share (Diluted)

Humanigen (Humanigen) Earnings per Share (Diluted) : $-0.54 (TTM As of Mar. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Humanigen Earnings per Share (Diluted)?

Humanigen's Earnings per Share (Diluted) for the three months ended in Mar. 2023 was $-0.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.54.

Humanigen's EPS (Basic) for the three months ended in Mar. 2023 was $-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.54.

Humanigen's EPS without NRI for the three months ended in Mar. 2023 was $-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.54.


Humanigen Earnings per Share (Diluted) Historical Data

The historical data trend for Humanigen's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humanigen Earnings per Share (Diluted) Chart

Humanigen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.65 -0.46 -2.42 -4.04 -0.79

Humanigen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.43 -0.23 0.16 -0.04

Competitive Comparison of Humanigen's Earnings per Share (Diluted)

For the Biotechnology subindustry, Humanigen's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humanigen's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humanigen's PE Ratio distribution charts can be found below:

* The bar in red indicates where Humanigen's PE Ratio falls into.



Humanigen Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Humanigen's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-70.73-0)/89.236
=-0.79

Humanigen's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2023 is calculated as

Diluted Earnings Per Share (Q: Mar. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-4.182-0)/119.080
=-0.04

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Humanigen  (OTCPK:HGENQ) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Humanigen Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Humanigen's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Humanigen (Humanigen) Business Description

Industry
Traded in Other Exchanges
N/A
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.
Executives
Dale Chappell 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Adrian Kilcoyne officer: Chief Medical Officer 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cameron Durrant director 90, FAIRMOUNT ROAD WEST, CALIFON NJ 07830-3330
Edward P. Jordan officer: Chief Commercial Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Yili Kevin Xie director C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Black Horse Capital Lp 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Black Horse Capital Master Fund Ltd. 10 percent owner C/O OPUS EQUUM, INC., P.O. BOX 788, DOLORES CO 81323
Nomis Bay Ltd. 10 percent owner C/O EOM MANAGEMENT LTD., ANDREW'S PLACE, 51 CHURCH ST., 5TH FLOOR, HAMILTON D0 HM12
Cheryl Buxton director 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cheval Holdings, Ltd. 10 percent owner P.O. BOX 309G, UGLAND HOUSE, GEORGETOWN, GRAND CAYMAN E9 KY1-1104
Black Horse Capital Management Llc 10 percent owner C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Rainer J. Boehm director C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
J Gregory Jester officer: Chief Financial Officer C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022

Humanigen (Humanigen) Headlines

From GuruFocus